Sorafenib is a multiple tyrosine kinase inhibitor, which inhibits tumor angiogenesis by inhibition of the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) signaling pathway and is the only FDA-approved systemic chemotherapeutic agent for the treatment of advanced HCC at this time [4, 5]. The gene discussed is VEGFA; the disease is neoplasm.